Asuka Pharmaceutical plans to approve the amendment of the Articles of Incorporation and transition to a Company with Audit & Supervisory Committee at the shareholders’ meeting scheduled for June 24, 2026. This aims to enhance management transparency and accelerate decision-making.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"Asuka Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-05-25","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4886-20260525-01.pdf","jir_short_summary":"Asuka Pharmaceutical plans to approve the amendment of the Articles of Incorporation and transition to a Company with Audit & Supervisory Committee at the shareholders' meeting scheduled for June 24, 2026. This aims to enhance management transparency and accelerate decision-making.","jir_summary":"### Overview of Amendments to the Articles of Incorporation\nAsuka Pharmaceutical will propose at the shareholders' meeting on June 24, 2026, the inclusion of their management philosophy in the Articles of Incorporation and the transition to a Company with Audit & Supervisory Committee. This positioning of management philosophy as the core of long-term value creation is intended to improve transparency and facilitate quicker decision-making. The revision of the Articles of Incorporation includes the establishment of the Audit & Supervisory Committee and procedural amendments for directors, with plans to review the officer structure and standards. After the transition, preparations for regulations will proceed to switch from a statutory audit committee to a Company with Audit & Supervisory Committee.\n\n### Future Schedule and Impact\nUpon approval by shareholders, the amendments to the Articles of Incorporation are expected to become effective on June 24, 2026. This is anticipated to improve management transparency and speed up decision-making, strengthening corporate governance. Changes in Directors and revisions of regulations will further enhance the company's governance structure. For shareholders and stakeholders, this will contribute to the stability of the company's management foundation and long-term growth.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#AsukaPharmaceutical, #IR, #JapanStocks","jir_key_figures":"Shareholders' Meeting Scheduled Date: June 24, 2026\nEffective Date of Amendments to the Articles of Incorporation: June 24, 2026\nTransition to a Company with Audit & Supervisory Committee","jir_meta_title":"\u3010Asuka Pharmaceutical\u3011Amendments to the Articles of Incorporation and Transition to Audit & Supervisory Committee | June 24, 2026","jir_meta_description":"Asuka Pharmaceutical plans to approve the inclusion of their management philosophy in the Articles of Incorporation and establish an Audit & Supervisory Committee at the shareholders' meeting on June 24, 2026. This is a key move to strengthen governance and ensure long-term growth.","jir_og_title":"\u3010Asuka Pharmaceutical\u3011Amendments to the Articles of Incorporation and Transition to Audit & Supervisory Committee | June 24, 2026","jir_og_description":"Asuka Pharmaceutical is scheduled to amend its Articles of Incorporation and establish an Audit & Supervisory Committee at the shareholders' meeting. This aims to enhance transparency and enable swift decision-making.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-54413","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n